Tarloxotinib bromide is under clinical development by Rain Oncology and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tarloxotinib bromide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tarloxotinib bromide overview
Tarloxotinib bromide is under development for treatment of non-squamous non small cell lung cancer (NSCLC) and squamous non-small cell lung cancer. The drug candidate is administered as intravenous infusion. It is a small-molecule prodrug that becomes active in the presence of tumor hypoxia. The drug candidate acts by targeting Erb-B family of tyrosine kinases and NRG1. It was also under development for solid tumors and and recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS), non-small cell lung cancer, breast cancer and ovarian cancer.
Rain Oncology overview
Rain Oncology, formerly Rain Therapeutics, is a biotechnology company that discovers, develops and translates cancer therapies. It is investigating its lead product candidate milademetan, an oral small molecule, inhibitor of mouse double minute 2 (MDM2) to treat well-differentiated (WD) and dedifferentiated (DD) liposarcoma, Merkel cell carcinoma, amplified and advanced solid tumors. The company is also evaluating a RAD52 inhibiting program targeting homologous recombination deficiencies (HRD+) and loss of function of several pathway constituents including BRCA1/2, PALB2 in breast, prostate, pancreatic, ovarian and other tumors. Rain Oncology is headquartered in Newark, California, the US.
For a complete picture of Tarloxotinib bromide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
